Everything below concerns reconstitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-06. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Belongs to the melanocortin agonist family |
| Key substitutions | Nle4 and D-Phe7 | Improve resistance to enzymatic degradation |
| Molecular formula | C50H69N15O9 | Approximately 1024 g/mol |
| Regulatory status | Not approved as a medicine | Distributed as a research chemical |
| Common synonyms | Melanotan II, MT-II, MT-2 | Spelling varies across sources |
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Michael Keegan, husband of Education Secretary Gillian Keegan and former chief executive of Fujitsu UK during the Post Office scandal, resigns from a part-time role with the Cabinet Office. The Shared Parental Leave and Pay (Bereavement) Bill, which guarantees parents immediate leave upon starting a job if their partner dies in childbirth, passes its first stage in the House of Commons. The UK government announces a fresh investigation into the sale of the Daily Telegraph after UAE-based RedBird IMI made an eleventh-hour change to the details of its bid to purchase the newspaper. 27 January – Kemi Badenoch, the business secretary, asks Henry Staunton to step down as chair of Post Office Limited after 13 months in the role, as the government moves to strengthen governance at the Post Office in the wake of the long-running Horizon IT scandal. 28 January – Former MP and cabinet minister Nadine Dorries says she would repay £16,876 in severance pay she received by mistake, as she was too old to qualify for the payment. 29 January – Labour MP Kate Osamor is suspended from the party after saying the Gaza conflict should be remembered as genocide in a post about Holocaust Memorial Day. George Freeman, the Conservative MP for Mid Norfolk, says that he resigned from his role in the Sunak ministry in November 2023 because he could not afford to pay his mortgage on the £118,300 ministerial salary after his mortgage increased from £800 to £2,000 per month.
Stewart appears in the Trinity series. He is the one to first attack the alien creature Konvikt, but his concentration suddenly snaps, and he starts muttering incoherently in binary code. A moment later, he spontaneously generates complex weapons from his body, unrelated to his ring. Later, he attempts to overexert himself to know how he generated those weapons by running a brutal training session against holographic Qwardian Thunderers, which does not work. He later shows Firestorm the machinery used to monitor the Cosmic Egg imprisoning Krona, but as he leaves again, he suffers from a relapse and start generating knives from his uniform, and it is revealed the entire system is broken. Later, on board the Antimatter Earth Crime Syndicate satellite, he again loses control and nearly brings down the satellite with his blasts. It is revealed these discharges are brought about due to John's absorption of a Qwardian superweapon, the Void Hound, which has been trying to escape its containment, or at least seize control of Stewart. After the sweeping, devastating effects of the spell engineered by Morgaine le Fey and Enigma, he is seen in an Earth under the control of a totalitarian Justice Society, where all Green Lanterns are forbidden to be. He eventually starts breaking down, and with the Void Hound gaining enough hold on him to force him to create a black hole which forces him back to Earth, he has no choice but to comply. The Void Hound is later revealed to be a servant of Krona, and its hold over John is broken when Krona is defeated.
Volanesorsen was approved by the European Medicines Agency (EMA) for the treatment of familial chylomicronaemia syndrome in May 2019. In January 2013 mipomersen (marketed as Kynamro) was approved by the FDA for the treatment of homozygous familial hypercholesterolemia. Inotersen received FDA approval for the treatment of hereditary transthyretin-mediated amyloidosis in October 2018. The application for inotersen was granted orphan drug designation. It was developed by Ionis Pharmaceuticals and licensed to Akcea Therapeutics. Patisiran (sold under Onpattro) was developed by Alnylam Pharmaceuticals, and also approved for use in the US and EU in 2018 with orphan drug designation. Its mechanism-of-action is the active substance of small interfering RNA (siRNA), which allows it to interfere with and block the production of transthyretin. As such, it was the first FDA-approved siRNA therapeutic.
Sources: en.wikipedia.org
Vericiguat, sold under the brand name Verquvo, is a medication used to reduce the risk of cardiovascular death and hospitalization in certain patients with heart failure after a recent acute decompensation event. It is taken by mouth. Vericiguat is a soluble guanylate cyclase (sGC) stimulator. Common side effects include low blood pressure and low red cell count (anemia). It was approved for medical use in the United States in January 2021, and for use in the European Union in July 2021.
=== Overall organization === Since a local-government reform in 2007, the general government organization in Denmark is carried out on three administrative levels: central government, regions, and municipalities. Regions administer mainly health care services, whereas municipalities administer primary education and social services. Municipalities in principle independently levy income and property taxes, but the scope for total municipal taxation and expenditure is closely regulated by annual negotiations between the municipalities and the Finance Minister of Denmark. At the central government level, the Ministry of Finance carries out the coordinating role of conducting economic policy. In 2012, the Danish parliament passed a Budget Law (effective from January 2014) which governs the over-all fiscal framework, stating among other things that the structural deficit must never exceed 0.5% of GDP, and that Danish fiscal policy is required to be sustainable, i.e. have a non-negative fiscal sustainability indicator. The Budget Law also assigned the role of independent fiscal institution (IFI, informally known as "fiscal watchdog") to the already-existing independent advisory body of the Danish Economic Councils.
=== Judiciary === Kennedy is a member of the Senate Judiciary Committee. As a member, he voted to confirm Justices Neil Gorsuch, Brett Kavanaugh, and Amy Coney Barrett. He voted against the nomination of Justice Ketanji Brown Jackson. Kennedy has defended the blue slip process for district court judges, saying that it "encourages bipartisan cooperation … The blue slip process makes our court system fairer and stronger. And that’s good for our democracy." He often asks judicial nominees basic questions about the Constitution during their confirmation process, occasionally stumping them. Kennedy has opposed the effort to add more justices to the Supreme Court, claiming it would "delegitimize" the Court. He has said he supports judges and justices who believe in "judicial restraint", adding, "Federal judges don't make law. They don't tell us what the law ought to be. They tell us what the law is." Kennedy opposed Congress establishing ethics standards for justices. He claimed such a move would violate the Constitution and called it "a crusade to undermine the United States' Supreme Court's legitimacy and the credibility of the federal judiciary." Kennedy's sharp questioning in the Judiciary Committee led to the eventual firing of former Department of Homeland Security Secretary Kristi Noem after he asked her why she had spent hundreds of millions of dollars on advertisements in which she prominently featured herself. Kennedy said he had spoken to President Trump about Noem's spending and that Trump was "mad as a mama wasp" when Noem claimed Trump had approved the spending.
Sources: en.wikipedia.org
The three substrates of this enzyme are asparagusic acid, reduced nicotinamide adenine dinucleotide (NADH), and a proton. Its products are 3-mercapto-2-mercaptomethylpropanoic acid and oxidised NAD+. This enzyme belongs to the family of oxidoreductases, specifically those acting on a sulfur group of donors with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is 3-mercapto-2-mercaptomethylpropanoate:NAD+ oxidoreductase. Other names in common use include asparagusate dehydrogenase, asparagusic dehydrogenase, asparagusate reductase (NADH2), and NADH2:asparagusate oxidoreductase.
Stable nuclei, and unstable nuclei with very long half-lives, follow a trend of stability evident when Z is plotted against N. For lighter nuclei less than N = 20, the line has the slope N = Z, while the heavier nuclei require additional neutrons to remain stable. Nuclei that are neutron- or proton-rich have excessive binding energy for stability, and the excess energy may convert a neutron to a proton or a proton to a neutron via the weak nuclear force, a process known as beta decay. Neutron-induced fission of U-235 emits a total energy of 207 MeV, of which about 200 MeV is recoverable, Prompt fission fragments amount to 168 MeV, which are easily stopped with a fraction of a millimeter. Prompt neutrons total 5 MeV, and this energy is recovered as heat via scattering in the reactor. However, many fission fragments are neutron-rich and decay via β− emissions. According to Lilley, "The radioactive decay energy from the fission chains is the second release of energy due to fission. It is much less than the prompt energy, but it is a significant amount and is why reactors must continue to be cooled after they have been shut down and why the waste products must be handled with great care and stored safely."
Wu (吴语): Jiangzhe people (江浙民系) Hui (徽语): Wannan people (皖南民系) Gan (赣语): Jiangxi people (江西民系) Xiang (湘语): Hunan people (湖南民系) Min (闽语): Minhai people (闽海民系) Hakka (客语): Hakka people (客家民系) Yue (粤语): Cantonese people (岭南民系) Pinghua (平话) and Tuhua (土话): Pingnan people (平南民系) Jin (晋语): Jinsui people (晋绥民系) Mandarin (官话): Northern people (北方民系) Northeastern (东北): Northeastern people (东北民系) Beijing (北平): Youyan people (幽燕民系) Jilu (冀鲁): Jilu people (冀鲁民系) Jiaoliao (胶辽): Jiaoliao people (胶辽民系) Central Plains (中原): Central Plains people (中原民系) Lanyin (兰银): Longyou people (陇右民系) Southwestern (西南): Southwestern people (西南民系) Jianghuai (江淮): Jianghuai people (江淮民系)
Sources: en.wikipedia.org
It is a synthetic cyclic peptide designed as an analog of alpha-melanocyte-stimulating hormone. It acts on melanocortin receptors and is best known from research into pigmentation. It is not an approved pharmaceutical product.
No regulatory agency has approved it for any indication. It is encountered as a research chemical sold outside pharmaceutical supply chains. Products marketed this way are not subject to the manufacturing and labeling requirements that apply to approved drugs.
Reports describe increased skin pigmentation as well as side effects such as nausea, flushing, and changes to existing moles. Much of the evidence comes from small studies and case reports rather than large trials. The long-term safety profile is therefore uncertain.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.